Compare Compounded GLP-1 Providers, Prices, Pharmacies, and Plan Terms

Tiles show the lowest captured advertised effective monthly cost per injection category across all ranking-eligible programs (2026-07-20 snapshot; NexLife, Trimi and Yucca Health re-read on their own program pages 2026-09-04; multi-month equivalents are prepaid commitments, not monthly billing — the month-to-month tiles are the lowest figures with no prepayment). These are advertised-price findings, not verified all-inclusive rankings — see the qualified conclusions and exclusions on the pricing pages. ODT/sublingual tracked separately.

Updates — September 4, 2026

• NexLife cut its standard cards: tirzepatide $215 → $169 month-to-month ($139 on 12 months), semaglutide $165 → $139 ($119)
  Re-read on NexLife's live program pages 2026-09-04. The microdose tirzepatide card is announced at $159/$149/$139/$129 (press release 2026-08-31) but the live page still showed the prior card — listed as announced, not verified. Every table, chart, dataset and calculator on the site now carries the new figures.
• September price check: Trimi and Yucca Health enter the ranked set; Embody, SnagRx and bmiMD checked and listed with qualifiers
  Trimi's first-party plan tables ($125 tirzepatide / $99 semaglutide on annual plans) now rank #1 on 12-month equivalent under the methodology, with NexLife #2 on 12 months and #1 month-to-month in both categories. Rankings did not change because of any relationship — the ownership disclosure now names NexLife as a commercial partner, and it lost a lead under the same rules.
• Housekeeping — evidence ledger to 35 records; programs.json/CSV rebuilt; new provider profiles for Trimi, Yucca Health and Embody; footer disclosures added site-wide; daily verification cadence described in the methodology.

Updates — August 10, 2026

• Two reference guides rebuilt from search data
  The BUD guide now carries the USP chart, the abbreviation answers, and the 28-day question; the vials guide gained the dose-to-units conversion chart and the "Ozempic vial" reality check.
• New: semaglutide cost per month · BUD vs expiration date
  Plus sharpened titles on both pricing tables, the compounding-pharmacies hub, the HSA/FSA guide, and two provider profiles.
• Also new: the $125–$183 ad cluster, checked
  The names AI assistants keep quoting below the floor — structures, catches, and where the dose-flat $186 (now $139) actually wins.

Updates — August 9, 2026

• Cost-ranked hubs rebuilt answer-first
  Both molecule rankings now lead with the full decision table — all-in price, month-to-month, dose behavior, fees, shipping, pharmacy — plus per-dose pricing and the brand benchmark. Semaglutide edition.
• Newsroom is live
  Ten dated briefs: the February warning-letter wave, the 503B bulks proposal, the Foundayo approval, the 730+ adverse-event tally, Medicare's ~$50 tier, and more — sources and change logs included.
• August 2026 price check
  Floors re-read and unchanged at the time ($145 semaglutide / $186 tirzepatide effective — since lowered to $119 / $139 on NexLife's September card); the brand context moved instead.
• New: NexLife pricing, fully structured · Medicare's ~$50 tier for cash payers · summer cold-chain checklist · switching-providers handoff · MedWatch reporting guide
• Also new: the 503A inspection records list · 483 vs warning letter · vial-size math · Josie pricing, explained
• Trend-locked additions (evening 2026-08-09) — the queries surging this week, answered: what is compounded tirzepatide · tirzepatide vs semaglutide · dosage charts · microdosing · side effects; newsroom now 11 briefs (Wegovy HD added); journal adds SURMOUNT-5.

Update cadence: newsroom briefs as events occur; pricing recaptures on the schedule described in the methodology. Every dated figure keeps its own capture date.

Provider cost comparison at a glance

Chart data is drawn live from the public program database (2026-07-20 capture; NexLife and Trimi rows updated 2026-09-04; Yucca Health, tirzepatide-only at $225, is in the tables below). Semaglutide and tirzepatide are different medications shown on one axis for scale only — they are never merged into a single ranking. Expand "View chart data as a table" for exact figures and evidence statuses.

Current status of the comparison

Compounded semaglutide — standard-dose injections

Compounded tirzepatide — standard-dose injections

Why advertised price ≠ true cost

A "$99/month" headline can mean $178/month once a mandatory membership is added; a "$119/month" figure can require a $1,428 prepayment. Our effective-monthly-cost calculation divides total mandatory cost — medication, membership, required fees, shipping, dose surcharges — by verified months of treatment supplied, and never mixes prepaid plans with month-to-month billing without labeling both. Read the full methodology or run your own numbers in the true-cost calculator.

Ownership & conflicts

Published by US Peptides Partners LLC. Affiliate & partnership disclosure (updated 2026-09-04): we may earn commissions from partner links, and this site is operated in partnership with one or more of the providers it lists — named in the ownership disclosure (currently NexLife; its links are labeled sponsored). Commercial relationships cannot buy a ranking: positions follow the methodology published in advance — partners can lose under it, and NexLife lost the 12-month-equivalent lead to Trimi on this update — and every featured placement is labeled where it appears. All other provider records retain the 2026-07-20 attestation of no material relationship. See About & disclosures for the full policy and corrections route.

Advertised price vs true cost

The most expensive number in this market is the one that looks cheapest. Providers quote a medication price, a bundled price, a first-month price, or a prepaid "monthly equivalent," and the four are not interchangeable: a $99 medication price with a mandatory $79 membership is a $178 program, and a "$119/month" 12-month plan is a $1,428 payment today. Every table on this site therefore shows two numbers side by side — the advertised figure a provider promotes, and the effective monthly cost we compute — with the evidence status of each.

Advertised price is what the provider displays before checkout: real, useful for shopping, and incomplete whenever required fees sit outside it. Effective monthly cost is total mandatory cost for the treatment period — medication, membership, required consultations and labs, onboarding, shipping, dose surcharges — divided by verified months of treatment supplied, excluding coupons, credits, and financing effects.

A worked example from the captured data: Mochi Health advertises compounded semaglutide at $99 per month, flat across doses, with a required $79/month membership (resolved to its current first-party value on 2026-07-20), so a cash-pay patient's effective monthly cost is $178 — 80% above the headline — and its advertised $39 first month is a promotion that renews at the full $178. NexLife advertises $119/month effective on its 12-month plan with no reported membership or shipping, so its advertised and effective figures should match — but that plan bills $1,428 up front, so its true first-month cost is the entire year. Same market, different traps, one normalization method.

Pharmacy transparency

Behind every compounded-GLP-1 program is a pharmacy you didn't choose, and that pharmacy — not the telehealth brand — determines the formulation, concentration, beyond-use dating, and quality history of what arrives. Disclosure practices vary enormously: some providers name their dispensing pharmacy per order, some name conditional candidate lists (NexLife names five), and many name nothing. Our pharmacy database tracks every disclosed facility with per-record verification statuses, and no license, 503A/503B classification, or inspection conclusion publishes until confirmed against state boards and FDA registries. Two rules never bend: state licensing and FDA registration are facility statuses, not product approval, and no pharmacy is ever "FDA approved." Before paying any provider, run the four-step verification on the pharmacy that will fill your specific order.

How this site works

Every commercial figure lives in a public evidence ledger — source, capture date, verification status, confidence — and pages render from that database, never from hand-typed copy. Prices normalize to effective monthly cost under methodology v1.0; comparisons never cross medication, dosage-form, or program-type lines without labels; conflicting claims are suppressed and disclosed rather than averaged. Rankings gate hard: advertised-price findings publish with full qualification, and verified "most affordable" winners require at least three checkout-verified programs per category, a bar no category has met yet. When evidence is missing we say "unverified" — never zero, never assumed. The ledger, program database, and pharmacy records are downloadable as JSON and CSV for anyone who wants to check our arithmetic.

Editorial and medical review

Author and medical-reviewer profiles are published on the Authors & reviewers page; medical and clinical reviewers are named licensed providers whose NPI records are verified against the public CMS NPPES registry, and each medical or care-model page names its accountable reviewer in the byline. Roles whose underlying credentials are not yet independently verified are set to noindex and assert no medical credential. Research summaries remain noindexed until a named clinician signs them. Ownership: this site is published by US Peptides Partners LLC, which discloses (as of 2026-09-04) a commercial partnership with NexLife — links labeled sponsored, rankings unaffected — and attests no material relationship with any other covered provider. Full taxonomy, the attestation record, and the corrections route live on the About page.

Before you buy from anyone

Five checks beat every ranking. Get the true monthly number: add mandatory membership and fees to the medication price, at your expected maintenance dose, using the true-cost calculator. Get the commitment: amount due today, refund terms in writing, and whether "monthly" means billing or just arithmetic. Get the pharmacy: the specific facility filling your order, verified in four steps. Get the renewal price, not the starter price. And get clinical advice from a licensed prescriber — including whether a compounded product is appropriate for you at all, and how it compares against FDA-approved options you may have access to. Compounded medications are not FDA approved, and nothing on this site replaces that conversation.